Atezolizumab/Bevacizumab for Advanced Renal Cell Carcinoma: Bradley McGregor, MD, and Toni Choueiri, MD

While metastatic renal cell carcinoma (RCC) has a five-year survival rate of only 10%, patients whose tumors have variant histology or sarcomatoid differentiation face an even more dismal outlook, with limited treatment options. In a study now published in the Journal of Clinical Oncology, a team of researchers led by Bradley McGregor, MD, and Toni Choueiri, MD, reported that atezolizumab in combination with bevacizumab significantly increased progression-free survival and improved outcomes in p...
Continue reading

Gregg Semenza, MD, PhD: The Role of HIF-1 and HIF-2 in Cancer

Gregg L. Semenza, MD, PhD, was recently awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work in isolating hypoxia inducible factor (HIF) 1, which controls genes that are involved in cells' adaptation to low oxygen levels, with implications for cancer, ischemia, and chronic lung disease. In this interview with i3 Health, Dr. Semenza discusses the involvement of HIF-1 and HIF-2 in cancer and shares insights on the progress that is being made in developing HIF-1 and HIF-2 i...
Continue reading

Post-Immunotherapy Axitinib for Patients With Renal Cell Carcinoma

For patients with metastatic renal cell carcinoma (RCC), checkpoint inhibitor therapy is the standard of care. However, if that doesn't work, vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitors can be the next option, but there is no prospective data on the efficacy of these drugs for RCC in this setting. In an attempt to provide evidence for the effectiveness of VEGF-R tyrosine kinase inhibitors for RCC previously treated with immune checkpoint inhibitors, researcher...
Continue reading

Nivolumab: Five-Year Survival for Melanoma, RCC, and NSCLC

​Five-year overall survival results have now been revealed for nivolumab in advanced melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC)."We report, to our knowledge, the longest combined clinical follow-up for patients with multiple cancer types receiving any anti–PD-L1 drug," the researchers comment in their secondary analysis of data from the phase I CA209-003 trial and expansion cohorts. This trial was the first multidose trial of nivolumab, an immunotherapy drug tha...
Continue reading

Avelumab/Axitinib Approved: Advanced Renal Cell Carcinoma

​The FDA has approved avelumab (Bavencio®, EMD Serono, Inc.) in combination with axitinib (Inlyta®, Pfizer Inc.) as first-line treatment for advanced renal cell carcinoma (RCC).Avelumab is an anti–programmed death ligand 1 (anti–PD-L1) antibody, a type of immune checkpoint inhibitor. Axitinib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), improves tumor infiltration by immune cells. It has antiangiogenic activity, meaning that it prevents tumors from grow...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.